

PNEUMOCOCCAL CONJUGATE VACCINE SCORECARD

MAIN FINDINGS

Full coverage of the pneumococcal conjugate vaccine (PCV) could prevent the deaths of 1,630,000 children under five by 2030

Twenty countries account for 70% of child lives saved with PCV by 2030 (see chart), including 14 in Africa and six in Asia


Fifteen of 20 countries are eligible for financial support from Gavi, including two yet to introduce PCV (Chad and Somalia) and ten have PCV coverage below 70% (Nigeria, India, DRCongo, Ethiopia, Angola, Chad Afghanistan, Somalia, Cameroon, and Indonesia)

Twelve of 20 countries are conflictaffected according to the World Bank (Nigeria, DRCongo, Ethiopia, Niger, Sudan, Chad, Afghanistan, Somalia, Mali, Cameroon, Mozambique, and Burkina Faso)

Seventeen of 20 countries have 1 million plus people in acute food insecurity at crisis and emergency levels according to the IPC Classification, including many children vulnerable to infectious diseases

Visit:
www.stoppneumonia.org/
everybreathcounts

Top 20 countries where PCV coverage can save the most children's lives by 2030



The deaths of 1.63 million children under five could be prevented by 2030 with one of the most powerful pneumonia-fighting vaccines - the pneumococcal conjugate vaccine (PCV) - according to the Vaccine Impact Modelling Consortium (VIMC).

The vast majority - 1.5 million or 94% - of lives saved are in 40 countries across Africa (28), Asia (9), and the Middle East (3), with many experiencing fragility and/or conflict and food shortages at crisis proportions. Thirty-three countries (80%) are eligible for financial assistance to introduce PCV from Gavi, the Vaccine Alliance (Gavi).

It is critical that these 40 governments protect at least 90% of their children with PCV by 2030, starting with those at greatest risk of death due to malnutrition and other risks.

Where governments are fragile and/or conflictaffected, international vaccine and humanitarian agencies must join forces to protect children with an integrated package of vaccines, food, and medicines.

PNEUMOCOCCAL CONJUGATE VACCINE SCORECARD

CALL TO ACTION

National governments should:

- 1. Accelerate PCV coverage to the Immunization Agenda 2030 target of at least 90%, prioritizing the populations of children at greatest risk of death from pneumonia
- 2. Deliver PCV vaccines alongside services to diagnose and treat child wasting
- 3. Leverage relationships with international vaccine agencies to access more affordable PCVs
- 4. Negotiate access to next generation PCVs that offer more protection at reasonable prices
- 5. Publish PCV coverage progress as part of national pneumonia control strategies

Where governments are fragile and unable to vaccinate or reach children with healthcare, international vaccine and humanitarian agencies must join forces to protect children.

Share:
#Vaccines4Life
#EveryBreathCounts



Photo: PCV introduction in India, JSI, 2021

HIGH RETURN ON PCV COVERAGE

High and sustained PCV coverage delivers:



Reductions in child pneumonia, meningitis, and sepsis deaths, accelerating achievement of Sustainable Development Goal 3.2 - a child mortality rate of at least 25 deaths per 1,000 births by 2030



Reductions in catastrophic health care costs for families required to pay the high costs of child pneumonia, meningitis, and sepsis hospitalization



Reductions in antimicrobial resistance as higher PCV vaccination means lower demand for antibiotics to treat pneumonia, meningitis, and sepsis

PCV INNOVATION

The World Health Organization (WHO) currently prequalifies three PCVs for children which offer protection against 10 and 13 strains of pneumococcal disease. But there are efforts underway to produce pneumococcal vaccines that protect against 14, 15, 20, and even 25 strains. If these efforts are successful, PCVs will become an even more effective tool in the fight to reduce pneumococcal deaths among children.

PCV-10: Protects against 10 strains and is manufactured by GlaxoSmithKline as Synflorix® (including serotypes 4 and 18C) and the Serum Institute of India as PNEUMOSIL® (including serotypes 6A and 19A)

PCV-13: Protects against 13 strains and is manufactured by Pfizer as Prev(e)nar®

PCV-14: Protects against 14 strains and is being developed by Biological E as BE-PCV14

PCV-15: Protects against 15 strains and is manufactured by Merck as VAXNEUVANCE® Approved for use in children in the USA in 2022

PCV-20: Pfizer (20vPnC) is currently conducting clinical trials with a pneumococcal vaccine for children that protects against 20 pneumococcal serotypes

PCV-25: Protects against 25 strains and is in early development by Inventprise and the Bill & Melinda Gates Foundation as IVT-PCV-25

PNEUMOCOCCAL CONJUGATE VACCINE SCORECARD

COUNTRY	CHILD DEATHS PREVENTED WITH PCV (2023-2030)	% PCV COVERAGE (2022)	GAVI ELIGIBILITY (2023)	POPULATION IN FOOD CRISIS (2023)
NIGERIA	210,000	60%		24,900,000
INDIA	189,000	66%		0
DRCONGO	110,000	64%		25,800,000
PAKISTAN	106,000	85%		11,800,000
ETHIOPIA	104,000	61%		19,000,000
CHINA	74,500	0%		0
ANGOLA	67,700	24%		1,000,000
NIGER	61,800	84%		3,300,000
BANGLADESH	49,300	99%		11,900.000
SUDAN	40,800	85%		20,300,000
TANZANIA	35,300	83%		1,100,000
CHAD	35,200	0%		1,900,000
AFGHANISTAN	33,300	67%		19,900.000
SOMALIA	32,800	0%		6,600,000
MALI	28,600	77%		1,300.000
CAMEROON	25,600	67%		3,000,000
UGANDA	25,100	90%		2,000,000
INDONESIA	23,400	6 %		0
MOZAMBIQUE	22,200	70%		3,100,000
BURKINA FASO	18,700	91%		3,400,000
SOUTH AFRICA	16,500	89%		0
YEMEN	15,400	74%		17,000,000
KENYA	15,200	91%		5,400,000
CÖTE D'IVOIRE	14,700	61%		0
MADAGASCAR	13,300	57%		2,200,000
PHILIPPINES	13,000	71%		0
BENIN	12,800	73%		0
SOUTH SUDAN	12,700	0%		7,800,000
ZAMBIA	12,700	90%		2,000,000
MYANMAR	12,300	57%		NA
BURUNDI	12,300	91%		2,300,000
GUINEA	11,300	0%		700,000
SENEGAL	11,300	88%		1,300,000
EGYPT	11,100	0%		NA
GHANA	10,000	99%		1,500,000
MALAWI	8,000	87%		3,800,000
NEPAL	7,900	83%		0
SIERRA LEONE	7,500	93%		1,200,000
RWANDA	7,400	98%		NA
IRAQ	6,300	0%		NA

These 40 countries are home to 94% of all 1,630,000 child lives that could be saved with PCV coverage by 2030 according to the Vaccine Impact Modelling Consortium (VIMC). Data for PCV coverage is from the 2022 WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), and data for food security (Phase 3 and above) from the Integrated Food Security Phase Classification (IPC).